Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · IEX Real-Time Price · USD
-0.020 (-1.63%)
Jun 14, 2024, 10:28 AM EDT - Market open

Company Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.

Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atossa Therapeutics, Inc.
Atossa Therapeutics logo
Country United States
Founded 2009
IPO Date Nov 8, 2012
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Dr. Steven C. Quay FCAP, M.D., Ph.D.

Contact Details

107 Spring Street
Seattle, Washington 98104
United States
Phone 206.588.0256

Stock Details

Ticker Symbol ATOS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001488039
CUSIP Number 04962H506
ISIN Number US04962H5063
Employer ID 26-4753208
SIC Code 2834

Key Executives

Name Position
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, Chief Executive Officer and President
Heather Rees CPA Senior Vice President of Finance and Principal Accounting Officer
Delly Behen P.H.R. Senior Vice President of Administration and Human Resources
Eric Van Zanten Vice President of Investor and Public Relations
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer

Latest SEC Filings

Date Type Title
May 23, 2024 EFFECT Notice of Effectiveness
May 23, 2024 DEF 14A Other definitive proxy statements
May 14, 2024 DEL AM Filing
May 13, 2024 S-3 Registration statement under Securities Act of 1933
May 13, 2024 10-Q Quarterly Report
May 13, 2024 8-K Current Report
May 10, 2024 ARS Filing
May 10, 2024 PRE 14A Other preliminary proxy statements
Apr 2, 2024 8-K/A [Amend] Current report
Apr 1, 2024 10-K Annual Report